Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, ...

Consuming a variety of flavonoid-rich foods can lower all-cause mortality and chronic disease risks, emphasizing the ...

Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.

Researchers at Colorado State University have developed a tool that can be used to switch a plant's key genetic traits on or ...